ESR1 and triple-negative breast carcinoma: Early-stage disease has a high 5-year survival rate, with 99% for estrogen receptor positive (ER+) tumors, 94% for human epidermal growth factor receptor 2 (HER2+) overexpressing tumors, and 85% for triple negative breast cancer (TNBC) [2].